Phaseline

Companies › Hangzhou Sciwind Biosciences

Hangzhou Sciwind Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Respiratory, Immunology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XW003 injection
GLP-1 receptor agonist
GLP1RPhase 3OSA - Obstructive Sleep Apnea; ObesityFeb 2027
Econoglutide Injection
GLP-1 receptor agonist
GLP1RPhase 3Knee OsteoarthritisMay 2028
ecnoglutide tablets
GLP-1 receptor agonist
GLP1RPhase 1Overweight and/or ObesityJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07243171ecnoglutide tabletsPhase 1Overweight and/or ObesityMetabolic and endocrineJan 2027
NCT07073417XW003 injectionPhase 2ObesityMetabolic and endocrineFeb 2027
NCT07387094XW003 injectionPhase 3OSA - Obstructive Sleep ApneaRespiratoryDec 2027
NCT07734311Econoglutide InjectionPhase 3Knee OsteoarthritisImmunologyMay 2028
NCT07434050XW003 injectionPhase 3OSA - Obstructive Sleep ApneaRespiratoryJun 2028

Targets

GLP1R (3)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals Innovent Biologics (Suzhou)

Companies built like this

Kailera Mediar Therapeutics Beijing QL Biopharmaceutical Beijing Dongfang Biotech Chendu DIAO Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.